Article

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy

2021-10-04

Abstract excerpt

Higher-resolution tumor-agnostic biomarkers that predict response to immune checkpoint inhibitor (ICI) therapy are needed. Mutation signatures reflect underlying oncogenic processes that can affect tumor immunogenicity, and thus potentially delineate ICI treatment response among tumor types. Systematic mutational signature analysis on all solid tumors in The Cancer Genome Atlas yielded eight distinct tumor genomic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 309dfb0c-7785-5631-8a7a-42b40d6bdfb4
DOI: 10.1101/2021.10.03.21264330

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapyDOI 10.1101/2021.10.03.21264330Read

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.Semantic proximity Read

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burdenSemantic proximity Read

Clinical and genomic characterization of mutational signatures across human cancers.Semantic proximity Read

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read

Pan-cancer analysis of tumor mutational burden and homologous recombination DNA damage repair by targeted next-generation sequencingSemantic proximity Read

An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.Semantic proximity Read

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read

Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.Semantic proximity Read

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Semantic proximity Read

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors.Semantic proximity Read

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read